Bugs & Drugs
I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens (just below) and pipeline reviews. Note in particular that a comparative Summary of the priority pathogens lists is provided. For my summary of incentives to support this pipeline, see this webpage. Corrections and amends gratefully received.
Priority Pathogen / Threat Lists
- By my count, five priority pathogen lists have been proposed / published to date:
- India 2021: Newsletter is here, report is here.
- CDC 2019: Newsletter is here, report itself is here.
- WHO 2017: Newsletter is here, report itself is here.
- CDC 2013: Report itself is here.
- ESKAPE list 2008-9: This is the grandfather/mother of them all! The original papers are here:
- (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
- (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12
To help you keep them organized, a comparative summary of the priority pathogen lists as a PowerPoint deck is here.
- Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class.
Pipeline Reviews
- Reviews by WHO
- WHO 2020: My newsletter is here (and includes a video chat with Peter Beyer, one of the key drivers of the report). The review itself is here.
- WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
- WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
- Reviews by the Pew Trusts (all updated as of March 2021; see also this newsletter)
- Independent pipeline reviews
- Clinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2020 (https://doi.org/10.1038/s41579-020-0340-0) is an extended commentary on the current pipeline by the group who did the WHO 2019 review.
- Clinical pipeline: Butler and Paterson, J Antibiot 2020 https://doi.org/10.1038/s41429-020-0291-8: Not open access, but you can view it online here.
- Commercial view of recently approved drugs: Alan Carr 2020: Newsletter is here. Alan’s regularly updated summary analyzes products approved in the US since 2009.
- Non-traditional products: Theuretzbacher and Piddock, Cell Host Microb 2019 (https://doi.org/10.1016/j.chom.2019.06.004) and Rex et al. Nat Commun 2019, https://doi.org/10.1038/s41467-019-11303-9: Focused reviews and discussions of non-traditional products. Go here for a newsletter about these two papers.
- Preclinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2019 (https://www.nature.com/articles/s41579-019-0288-0) surveys 400+ active preclinical programs.
- Access- and Stewardship-focused reviews
Global Health Security: G7, BARDA Ventures, excellent ATMF report on saving small companies!
Dear All, On the theme of global health security, today’s note covers 3 exciting, overlapping items. Here we go… First, the G7 leaders have agreed to sign the Carbis Bay Declaration covering global health, economic stability, climate and more. Specifically related to health in a section entitled “End the pandemic and prepare for the future”, we have
Ways to talk about AMR / Video chat with Maryn McKenna
Dear All, Explaining AMR to our colleagues is not easy! I wrote in a 30 Oct 2019 newsletter about what Wellcome Trust learned on this point when they interviewed 12,000 people in Germany, India, Japan, Kenya, the UK, the USA and Thailand — in brief, there are universal themes that improve the likelihood that your message will
